OSTEOARTHRITIS
Synovial biomarkers and clincial scores of Orthovisc versus Hylan G-F20 in knee OA treatment
Ann Clin Lab Sci. 2004 Summer;34(3):330-540 patients with knee osteoarthritis were randomized to three weekly injections of either Orthovisc (Anika Therapeutics) or Hylan G-F20 (Synvisc; Genzyme). Primary outcomes were synovial fluid concentrations of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). Clinical outcome on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) was also assessed. Results demonstrated significant within-group reductions in both groups for ICAM-1, VCAM-1, and WOMAC scores from baseline to 3 weeks, with no significant between-group differences observed.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
